Drug Combination Details
| General Information of the Combination (ID: C50091) | |||||
|---|---|---|---|---|---|
| Name | Mycophenolate mofetil NP Info | + | Tacrolimus Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lupus nephritis
[ICD-11: 4A40]
|
Phase 4 | [1] | ||
|
Renal failure
[ICD-11: GB60]
|
Investigative | [2] | |||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MKI67 | Molecule Info | ||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Mycophenolate mofetil alone and in combination with tacrolimus inhibits the proliferation of HT-29 human colonic adenocarcinoma cell line and might interfere with colonic tumorigenesis. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| In-vivo Model | Clinical Trial | |||||
| Experimental
Result(s) |
The introduction of MMF combined with the reduction of at least 50% of CNI dose allowed the renal function of liver transplant recipients to significantly improve at 1 year, without any rejection episode and without significant secondary effects. | |||||
